Pardes Biosciences, Inc.
NASDAQ: PRDS0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Thomas G. Wiggans
- Employees
- 57
- Headquarters
- Carlsbad, United States
- IPO year
- 2021
- Market cap
- $135.2M
- Website
- https://www.pardesbio.com
Loading PRDS…
Loading profile data…Frequently asked questions about PRDS
What does Pardes Biosciences, Inc. (PRDS) do?
Pardes Biosciences, Inc. is a clinical-stage biopharmaceutical firm dedicated to identifying, developing, and marketing groundbreaking treatments. The company's core objective is to improve outcomes for patients battling life-threatening illnesses. Its primary investigational therapy, PBI-0451, is currently progressing through clinical developme...
Where does PRDS trade?
Pardes Biosciences, Inc. (PRDS) trades on the NASDAQ Global Market.
What sector is PRDS in?
Pardes Biosciences, Inc. (PRDS) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Pardes Biosciences, Inc.?
Thomas G. Wiggans is the chief executive officer of Pardes Biosciences, Inc. (PRDS).
Where is Pardes Biosciences, Inc. headquartered?
Pardes Biosciences, Inc. is headquartered in United States.
Does PRDS pay a dividend?
Pardes Biosciences, Inc. (PRDS) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did PRDS go public?
Pardes Biosciences, Inc. (PRDS) completed its initial public offering in 2021.